(R)-4-Methyloxazolidin-2-one → (R)-3-{6-[4-(4-chlorobenzoyl)piperidine-1-carbonyl]pyridin-3-yl}-4-methyloxazolidin-2-one

HRID 1803972

Reaktionsgleichung

Reaktionsgleichung von HRID 1803972
Br[C:2]1[CH:3]=[CH:4][C:5]([C:8]([N:10]2[CH2:15][CH2:14][CH:13]([C:16](=[O:24])[C:17]3[CH:22]=[CH:21][C:20]([Cl:23])=[CH:19][CH:18]=3)[CH2:12][CH2:11]2)=[O:9])=[N:6][CH:7]=1.[CH3:25][C@@H:26]1[CH2:30][O:29][C:28](=[O:31])[NH:27]1>>[Cl:23][C:20]1[CH:21]=[CH:22][C:17]([C:16]([CH:13]2[CH2:14][CH2:15][N:10]([C:8]([C:5]3[N:6]=[CH:7][C:2]([N:27]4[C@H:26]([CH3:25])[CH2:30][O:29][C:28]4=[O:31])=[CH:3][CH:4]=3)=[O:9])[CH2:11][CH2:12]2)=[O:24])=[CH:18][CH:19]=1

Komponenten

3

Edukt 2

HCID 2734858(R)-4-Methyloxazolidin-2-oneHCID 58484577(5-Bromopyridin-2-yl)[4-(4-chlorobenzoyl)piperidin-1-yl]methanone

Produkt 1

HCID 54755119(R)-3-{6-[4-(4-chlorobenzoyl)piperidine-1-carbonyl]pyridin-3-yl}-4-methyloxazolidin-2-oneAusbeute 83,4 %

Versuchsvorschrift

By reaction and treatment in the same manner as in Preparation Example 31 and using (5-bromopyridin-2-yl)[4-(4-chlorobenzoyl)piperidin-1-yl]methanone (2.4 g) described in Preparation Example 35 and (R)-4-methyloxazolidin-2-one (728 mg) described in Preparation Example 25, the title compound (2.1 g) was obtained.

Aufarbeitung

  1. customBy reaction and treatment in the same manner
  2. customas in Preparation Example 31
  3. customdescribed in Preparation Example 25

Quellen und Nachweise

ORD-Eintrag
ord-5dc47467ef784151ab188b492d73ec0b
Quelldatensatz
uspto-grants-2013_01
Patentnummer
US08354401B2

Verknüpfte Notizen

Wird geladen…